Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease

Progress in Neurobiology

Volumn 97, Issue 1, 2012, Pages 1-13

  Xu, Yunqi ^a   Yan, Junqiang ^a   Zhou, Peng ^a   Li, Jiejie ^a   Gao, Huimin ^a   Xia, Ying ^b   Wang, Qing ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Alzheimer's disease; Cognitive dysfunction; Neurodegeneration; Parkinson disease; Receptors

Indexed keywords

BETA ADRENERGIC RECEPTOR; CHOLINERGIC RECEPTOR; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE 1; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; LEVODOPA; MITOGEN ACTIVATED PROTEIN KINASE 3; N [4 (2 CYANOPHENYL) 1 PIPERAZINYLMETHYL] 3 METHYLBENZAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PERGOLIDE; SEROTONIN 1A RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN RECEPTOR; TANDOSPIRONE;

ALZHEIMER DISEASE; ANXIETY DISORDER; COGNITIVE DEFECT; DEMENTIA; HUMAN; IMMUNOHISTOCHEMISTRY; MINI MENTAL STATE EXAMINATION; NEUROMODULATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VERBAL MEMORY; WHOLE BODY PET;

ALZHEIMER DISEASE; COGNITION DISORDERS; HUMANS; PARKINSON DISEASE; RECEPTORS, NEUROTRANSMITTER;

EID: 84862789284     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2012.02.002     Document Type: Review

References (184)

1. Amadoro G., Ciotti M.T., Costanzi M., Cestari V., Calissano P., Canu N. NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:2892-2897.
2. Antonini A., Schwarz J., Oertel W.H., Pogarell O., Leenders K.L. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride. Mov. Disord. 1997, 12:33-38.
3. Antonini A., Vontobel P., Psylla M., Günther I., Maguire P.R., Missimer J., Leenders K.L. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch. Neurol. 1995, 52(12):1183-1190.
4. Antonini A., Leenders K.L., Vontobel P., Maguire R.P., Missimer J., Psylla M., Gunther I. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 1997, 120(Pt 12):2187-2195.
5. Auld D.S., Kornecook T.J., Bastianetto S., Quirion R. Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog. Neurobiol. 2002, 68:209-245.
6. Barrantes F.J., Borroni V., Vallés S. Neuronal nicotinic acetylcholine receptor-cholesterol crosstalk in Alzheimer's disease. FEBS Lett. 2010, 584(9):1856-1863.
7. Beaulieu J.M., Gainetdinov R.R. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 2011, 63:182-217.
8. Beaulieu J.M., Gainetdinov R.R., Caron M.G. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol. Sci. 2007, 28:166-172.
9. Beaulieu J.M., Sotnikova T.D., Gainetdinov R.R., Caron M.G. Paradoxical striatal cellular signaling responses to psychostimulants in hyperactive mice. J. Biol. Chem. 2006, 281:32072-32080.
10. Beaulieu J.M., Tirotta E., Sotnikova T.D., Masri B., Salahpour A., Gainetdinov R.R., Borrelli E., Caron M.G. Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J. Neurosci. 2007, 27:881-885.
11. Belujon P., Bezard E., Taupignon A., Bioulac B., Benazzouz A. Noradrenergic modulation of subthalamic nucleus activity: behavioral and electrophysiological evidence in intact and 6-hydroxydopamine-lesioned rats. J. Neurosci. 2007, 27(36):9595-9606.
12. Bi H., Sze C.I. N-methyl-d-aspartate receptor subunit NR2A and NR2B messenger RNA levels are altered in the hippocampus and entorhinal cortex in Alzheimer's disease. J. Neurol. Sci. 2002, 200(1-2):11-18.
13. Bitner R.S., Bunnelle W.H., Anderson D.J., Briggs C.A., Buccafusco J., et al. Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. J. Neurosci. 2007, 27(39):10578-10587.
14. Blin J., Baron J.C., Dubois B., Crouzel C., Fiorelli M., Attar-Levy D., Pillon B., Fournier D., Vidailhet M., Agid Y. Loss of brain 5-HT2 receptors in Alzheimer's disease. In vivo assessment with positron emission tomography and [18F]setoperone. Brain 1993, 116(Pt 3):497-510.
15. Blundell J., Adamec R. The NMDA receptor antagonist CPP blocks the effects of predator stress on pCREB in brain regions involved in fearful and anxious behavior. Brain Res. 2007, 1136(1):59-76.
16. Boileau I., Guttman M., Rusjan P., Adams J.R., Houle S., Tong J., Hornykiewicz O., Furukawa Y., Wilson A.A., Kapur S., Kish S.J. Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease. Brain 2009, 132:1366-1375.
17. Cash R., Ruberg M., Raisman R., Agid Y. Adrenergic receptors in Parkinson's disease. Brain Res. 1984, 322:269-275.
18. Cash R., Lasbennes F., Sercombe R., Seylaz J., Agid Y. Adrenergic receptors on cerebral microvessels in control and Parkinsonian subjects. Life Sci. 1985, 37:531-536.
19. Cash R., Raisman R., Lanfumey L., Ploska A., Agid Y. Cellular localization of adrenergic receptors in rat and human brain. Brain Res. 1986, 370:127-135.
20. Chang K.T., Berg D.K. Voltage-gated channels block nicotinic regulation of CREB phosphorylation and gene expression in neurons. Neuron 2001, 32:855-865.
21. Cheesman A.L., Barker R.A., Lewis S.J., Robbins T.W., Owen A.M., Brooks D.J. Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson's disease. J. Neurol. Neurosurg. Psychiatr. 2005, 76:1204-1210.
22. Chen L., Wang H., Zhang Z., Li Z., He D., Sokabe M. DMXB (GTS-21) ameliorates the cognitive deficits in beta amyloid(25-35(-)) injected mice through preventing the dysfunction of alpha7 nicotinic receptor. J. Neurosci. Res. 2010, 88:1784-1794.
23. Contreras F., Fouillioux C., Bolivar A., Simonovis N., Hernandez-Hernandez R., Armas-Hernandez M.J., Velasco M. Dopamine, hypertension and obesity. J. Hum. Hypertens. 2002, 16(Suppl. 1):S13-S17.
24. Costa A., Peppe A., Dell'Agnello G., Caltagirone C., Carlesimo G.A. Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory. Neuropsychologia 2009, 47(5):1374-1381.
25. Counts S.E., He B., Che S., Ikonomovic M.D., DeKosky S.T., Ginsberg S.D., Mufson E.J. Alpha7 nicotinic receptor up-regulation in cholinergic basal forebrain neurons in Alzheimer disease. Arch. Neurol. 2007, 64:1771-1776.
26. Cropley V.L., Fujita M., Bara-Jimenez W., Brown A.K., Zhang X.Y., Sangare J., Herscovitch P., Pike V.W., Hallett M., Nathan P.J., Innis R.B. Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA. Psychiatr. Res. 2008, 163:171-182.
27. Da Silva Costa V., Duchatelle P., Boulouard M., Dauphin F. Selective 5-HT6 receptor blockade improves spatial recognition memory and reverses age-related deficits in spatial recognition memory in the mouse. Neuropsychopharmacology 2009, 34(2):488-500.
28. Danbolt N.C. Glutamate uptake. Prog. Neurobiol. 2001, 65(1):1-105.
29. de Bartolomeis A., Fiore G., Iasevoli F. Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis. Curr. Pharm. Des. 2005, 11(27):3561-3594.
30. De Felice F.G., Velasco P.T., Lambert M.P., Viola K., Fernandez S.J., Ferreira S.T., Klein W.L. Abeta oligomers induce neuronal oxidative stress through an N-methyl-d-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J. Biol. Chem. 2007, 282:11590-11601.
31. Decker H., Jurgensen S., Adrover M.F., Brito-Moreira J., Bomfim T.R., Klein W.L., Epstein A.L., De Felice F.G., Jerusalinsky D., Ferreira S.T. N-methyl-d-aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid-beta peptide oligomers. J. Neurochem. 2010, 115:1520-1529.
32. Del Bel E.A., Slater P. Binding to the glycine site of the NMDA receptor complex in brains of patients with Alzheimer's disease. Neurosci. Lett. 1991, 131:75-78.
33. Dunah A.W., Wang Y., Yasuda R.P., Kameyama K., Huganir R.L., Wolfe B.B., Standaert D.G. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-d-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol. Pharmacol. 2000, 57:342-352.
34. Dziewczapolski G., Glogowski C.M., Masliah E., Heinemann S.F. Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease. J. Neurosci. 2009, 29:8805-8815.
35. El-Ghundi M., O'Dowd B.F., George S.R. Insights into the role of dopamine receptor systems in learning and memory. Rev. Neurosci. 2007, 18:37-66.
36. Ellis J.R., Villemagne V.L., Nathan P.J., Mulligan R.S., Gong S.J., Chan J.G., Sachinidis J., O'Keefe G.J., Pathmaraj K., Wesnes K.A., Savage G., Rowe C.C. Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study. Neurobiol. Learn. Mem. 2008, 90:404-412.
37. Faghih R., Gfesser G.A., Gopalakrishnan M. Advances in the discovery of novel positive allosteric modulators of the alpha7 nicotinic acetylcholine receptor. Recent Pat. CNS Drug Discov. 2007, 2:99-106.
38. Fang M., Li J., Tiu S.C., Zhang L., Wang M., Yew D.T. N-methyl-d-aspartate receptor and apoptosis in Alzheimer's disease and multiinfarct dementia. J. Neurosci. Res. 2005, 81:269-274.
39. Fang X., Sugiyama K., Akamine S., Namba H. The stepping test and its learning process in different degrees of unilateral striatal lesions by 6-hydroxydopamine in rats. Neurosci. Res. 2006, 55(4):403-409.
40. Fetsko L.A., Xu R., Wang Y. Effects of age and dopamine D2L receptor-deficiency on motor and learning functions. Neurobiol. Aging 2005, 26(4):521-530.
41. 2+-permeable AMPA receptors recruited by CaM-kinase I. J. Neurosci. 2010, 30(35):11565-11575.
42. Garcia-Alloza M., Hirst W.D., Chen C.P., Lasheras B., Francis P.T., Ramirez M.J. Differential involvement of 5-HT(1B/1D) and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer's disease. Neuropsychopharmacology 2004, 29:410-416.
43. Gerfen C.R., Miyachi S., Paletzki R., Brown P. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J. Neurosci. 2002, 22(12):5042-5054.
44. Ghahremani M.H., Forget C., Albert P.R. Distinct roles for Galpha(i)2 and Gbetagamma in signaling to DNA synthesis and Galpha(i)3 in cellular transformation by dopamine D2S receptor activation in BALB/c 3T3 cells. Mol. Cell. Biol. 2000, 20:1497-1506.
45. Gong Y., Lippa C.F., Zhu J., Lin Q., Rosso A.L. Disruption of glutamate receptors at Shank-postsynaptic platform in Alzheimer's disease. Brain Res. 2009, 1292:191-198.
46. Gubbins E.J., Gopalakrishnan M., Li J. Alpha7 nAChR-mediated activation of MAP kinase pathways in PC12 cells. Brain Res. 2010, 1328:1-11.
47. Gubellini P., Pisani A., Centonze D., Bernardi G., Calabresi P. Metabotropic glutamate receptors and striatal synaptic plasticity: implications for neurological diseases. Prog. Neurobiol. 2004, 74(5):271-300.
48. Guetg N., Abdel Aziz S., Holbro N., Turecek R., Rose T., Seddik R., Gassmann M., Moes S., Jenoe P., Oertner T.G., Casanova E., Bettler B. NMDA receptor-dependent GABAB receptor internalization via CaMKII phosphorylation of serine 867 in GABAB1. Proc. Natl. Acad. Sci. 2010, 107(31):13924-13929.
49. Gulyás B., Pavlova E., Kása P., Gulya K., Bakota L. Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography. Neurochem. Int. 2011, 58(1):60-68.
50. Hallett P.J., Standaert D.G. Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol. Ther. 2004, 102:155-174.
51. Hallett P.J., Spoelgen R., Hyman B.T., Standaert D.G., Dunah A.W. Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking. J. Neurosci. 2006, 26(17):4690-4700.
52. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
53. Harré E.M., Galic M.A., Mouihate A., Noorbakhsh F., Pittman Q.J. Neonatal inflammation produces selective behavioural deficits and alters N-methyl-d-aspartate receptor subunit mRNA in the adult rat brain. Eur. J. Neurosci. 2008, 27(3):644-653.
54. Harrington D.L., Haaland K.Y., Hermanowicz N. Temporal processing in the basal ganglia. Neuropsychology 1998, 12(1):3-12.
55. Hasselbalch S.G., Madsen K., Svarer C., Pinborg L.H., Holm S., Paulson O.B., Waldemar G., Knudsen G.M. Reduced 5-HT2A receptor binding in patients with mild cognitive impairment. Neurobiol. Aging 2008, 29:1830-1838.
56. 2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade. J. Neurosci. 2000, 20:8987-8995.
57. Hernandez C.M., Kayed R., Zheng H., Sweatt J.D., Dineley K.T. Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. J. Neurosci. 2010, 30:2442-2453.
58. Hirst W.D., Stean T.O., Rogers D.C., Sunter D., Pugh P., Moss S.F., Bromidge S.M., Riley G., Smith D.R., Bartlett S., Heidbreder C.A., Atkins A.R., Lacroix L.P., Dawson L.A., Foley A.G., Regan C.M., Upton N. SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur. J. Pharmacol. 2006, 553:109-119.
59. Hoyer D., Martin G. 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology 1997, 36(4-5):419-428.
60. Hu M., Liu Q.S., Chang K.T., Berg D.K. Nicotinic regulation of CREB activation in hippocampal neurons by glutamatergic and nonglutamatergic pathways. Mol. Cell. Neurosci. 2002, 21:616-625.
61. Huot P., Fox S.H., Brotchie J.M. The serotonergic system in Parkinson's disease. Prog. Neurobiol. 2011, 95(2):163-212.
62. Hurley M.J., Jenner P. What has been learnt from study of dopamine receptors in Parkinson's disease?. Pharmacol. Ther. 2006, 111:715-728.
63. Hynd M.R., Scott H.L., Dodd P.R. Differential expression of N-methyl-d-aspartate receptor NR2 isoforms in Alzheimer's disease. J. Neurochem. 2004, 90:913-919.
64. Ikonomovic M.D., Mizukami K., Warde D., Sheffield R., Hamilton R., Wenthold R.J., Armstrong D.M. Distribution of glutamate receptor subunit NMDAR1 in the hippocampus of normal elderly and patients with Alzheimer's disease. Exp. Neurol. 1999, 160:194-204.
65. Impey S., Obrietan K., Storm D.R. Making new connections: role of ERK/MAP kinase signaling in neuronal plasticity. Neuron 1999, 23:11-14.
66. Inoue Y., Wagner H.N., Wong D.F., Links J.M., Frost J.J., Dannals R.F., Rosenbaum A.E., Takeda K., Di Chiro G., Kuhar M.J. Atlas of dopamine receptor images (PET) of the human brain. J. Comput. Assist. Tomogr. 1985, 9:129-140.
67. Janssen W.G., Vissavajjhala P., Andrews G., Moran T., Hof P.R., Morrison J.H. Cellular and synaptic distribution of NR2A and NR2B in macaque monkey and rat hippocampus as visualized with subunit-specific monoclonal antibodies. Exp. Neurol. 2005, 191(Suppl. 1):S28-S44.
68. Ji D., Lape R., Dani J.A. Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity. Neuron 2001, 31:131-141.
69. Johnson P.L., Shekhar A. Panic-prone state induced in rats with GABA dysfunction in the dorsomedial hypothalamus is mediated by NMDA receptors. J. Neurosci. 2006, 26(26):7093-7104.
70. Jones C.K., Brady A.E., Davis A.A., Xiang Z., Bubser M., et al. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J. Neurosci. 2008, 28(41):10422-10433.
71. Kaasinen V., Aalto S., Nagren K., Hietala J., Sonninen P., Rinne J.O. Extrastriatal dopamine D(2) receptors in Parkinson's disease: a longitudinal study. J. Neural Transm. 2003, 110:591-601.
72. Kaasinen V., Nagren K., Hietala J., Oikonen V., Vilkman H., Farde L., Halldin C., Rinne J.O. Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease. Neurology 2000, 54:1482-1487.
73. Kalaria R.N., Harik S.I. Increased alpha 2- and beta 2-adrenergic receptors in cerebral microvessels in Alzheimer disease. Neurosci. Lett. 1989, 106:233-238.
74. Kalaria R.N., Andorn A.C. Adrenergic receptors in aging and Alzheimer's disease: decreased alpha 2-receptors demonstrated by [3H]p-aminoclonidine binding in prefrontal cortex. Neurobiol. Aging 1991, 12:131-136.
75. Kalaria R.N., Andorn A.C., Harik S.I. Alterations in adrenergic receptors of frontal cortex and cerebral microvessels in Alzheimer's disease and aging. Prog. Clin. Biol. Res. 1989, 317:367-374.
76. Kalaria R.N., Andorn A.C., Tabaton M., Whitehouse P.J., Harik S.I., Unnerstall J.R. Adrenergic receptors in aging and Alzheimer's disease: increased beta 2-receptors in prefrontal cortex and hippocampus. J. Neurochem. 1989, 53:1772-1781.
77. Kato G., Agid Y. Acetylcholine receptors (author's transl.). Nouv. Presse Med. 1979, 8:2407-2411.
78. Kemppainen N., Ruottinen H., Nagren K., Rinne J.O. PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD. Neurology 2000, 55:205-209.
79. Kemppainen N., Laine M., Laakso M.P., Kaasinen V., Nagren K., Vahlberg T., Kurki T., Rinne J.O. Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease. Eur. J. Neurosci. 2003, 18:149-154.
80. Knudsen G.M., Karlsborg M., Thomsen G., Krabbe K., Regeur L., Nygaard T., Videbaek C., Werdelin L. Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy. Eur. J. Nucl. Med. Mol. Imaging 2004, 31:1631-1638.
81. Kurup P., Zhang Y., Xu J., Venkitaramani D.V., Haroutunian V., Greengard P., Nairn A.C., Lombroso P.J. Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61. J. Neurosci. 2010, 30:5948-5957.
82. Lai M.K., Tsang S.W., Francis P.T., Esiri M.M., Keene J., Hope T., Chen C.P. Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease. Brain Res. 2003, 974:82-87.
83. Lai M.K., Tsang S.W., Francis P.T., Keene J., Hope T., Esiri M.M., Spence I., Chen C.P. Postmortem serotoninergic correlates of cognitive decline in Alzheimer's disease. Neuroreport 2002, 13:1175-1178.
84. Lai M.K., Tsang S.W., Francis P.T., Esiri M.M., Hope T., Lai O.F., Spence I., Chen C.P. [3H]GR113808 binding to serotonin 5-HT(4) receptors in the postmortem neocortex of Alzheimer disease: a clinicopathological study. J. Neural Transm. 2003, 110:779-788.
85. Lai M.K., Tsang S.W., Alder J.T., Keene J., Hope T., Esiri M.M., Francis P.T., Chen C.P. Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer's disease. Psychopharmacology (Berlin) 2005, 179:673-677.
86. Laureys G., Clinckers R., Gerlo S., Spooren A., Wilczak N., Kooijman R., Smolders I., Michotte Y., De Keyser J. Astrocytic beta(2)-adrenergic receptors: from physiology to pathology. Prog. Neurobiol. 2010, 91(3):189-199.
87. Li Y., Huang X.F., Deng C., Meyer B., Wu A., Yu Y., Ying W., Yang G.Y., Yenari M.A., Wang Q. Alterations in 5-HT2A receptor binding in various brain regions among 6-hydroxydopamine-induced Parkinsonian rats. Synapse 2010, 64(3):224-230.
88. Lilja A.M., Porras O., Storelli E., Nordberg A., Marutle A. Functional interactions of fibrillar and oligomeric amyloid-beta with alpha7 nicotinic receptors in Alzheimer's disease. J. Alzheimers Dis. 2011, 23:335-347.
89. Liu H.P., Lin W.Y., Liu S.H., Wang W.F., Tsai C.H., Wu B.T., Wang C.K., Tsai F.J. Genetic variation in N-methyl-d-aspartate receptor subunit NR3A but not NR3B influences susceptibility to Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2009, 28:521-527.
90. Marcos B., Chuang T.T., Gil-Bea F.J., Ramirez M.J. Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat. Br. J. Pharmacol. 2008, 155:434-440.
91. Mattila P.M., Roytta M., Lonnberg P., Marjamaki P., Helenius H., Rinne J.O. Choline acetytransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment. Acta Neuropathol. 2001, 102:160-166.
92. Meana J.J., Barturen F., Garro M.A., Garcia-Sevilla J.A., Fontan A., Zarranz J.J. Decreased density of presynaptic alpha 2-adrenoceptors in postmortem brains of patients with Alzheimer's disease. J. Neurochem. 1992, 58:1896-1904.
93. Medeiros R., Kitazawa M., Caccamo A., Baglietto-Vargas D., Estrada-Hernandez T., Cribbs D.H., Fisher A., Laferla F.M. Loss of muscarinic M(1) receptor exacerbates Alzheimer's disease-like pathology and cognitive decline. Am. J. Pathol. 2011, 179(2):980-991.
94. Mehta M.A., Sahakian B.J., McKenna P.J., Robbins T.W. Systemic sulpiride in young adult volunteers simulates the profile of cognitive deficits in Parkinson's disease. Psychopharmacology (Berlin) 1999, 146:162-174.
95. Meneses A., Hong E. 5-HT1A receptors modulate the consolidation of learning in normal and cognitively impaired rats. Neurobiol. Learn. Mem. 1999, 71:207-218.
96. Meoni P., Bunnemann B.H., Kingsbury A.E., Trist D.G., Bowery N.G. NMDA NR1 subunit mRNA and glutamate NMDA-sensitive binding are differentially affected in the striatum and pre-frontal cortex of Parkinson's disease patients. Neuropharmacology 1999, 38:625-633.
97. *-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch. Gen. Psychiatr. 2009, 66:866-877.
98. Miranda S., Opazo C., Larrondo L.F., Muñoz F.J., Ruiz F., Leighton F., Inestrosa N.C. The role of oxidative stress in the toxicity induced by amyloid beta-peptide in Alzheimer's disease. Prog. Neurobiol. 2000, 62(6):633-648.
99. Mishizen-Eberz A.J., Rissman R.A., Carter T.L., Ikonomovic M.D., Wolfe B.B., Armstrong D.M. Biochemical and molecular studies of NMDA receptor subunits NR1/2A/2B in hippocampal subregions throughout progression of Alzheimer's disease pathology. Neurobiol. Dis. 2004, 15:80-92.
100. Mitchell E.S., Neumaier J.F. 5-HT6 receptors: a novel target for cognitive enhancement. Pharmacol. Ther. 2005, 108:320-333.
101. Mitsis E.M., Reech K.M., Bois F., Tamagnan G.D., Macavoy M.G., Seibyl J.P., Staley J.K., van Dyck C.H. 123I-5-IA-85380 SPECT imaging of nicotinic receptors in Alzheimer disease and mild cognitive impairment. J. Nucl. Med. 2009, 50:1455-1463.
102. Miwa J.M., Stevens T.R., King S.L., Caldarone B.J., Ibanez-Tallon I., et al. The prototoxin lynx1 acts on nicotinic acetylcholine receptors to balance neuronal activity and survival in vivo. Neuron 2006, 51(5):587-600.
103. Mizukawa K., McGeer E.G., McGeer P.L. Autoradiographic study on dopamine uptake sites and their correlation with dopamine levels and their striata from patients with Parkinson disease. Alzheimer disease, and neurologically normal controls. Mol. Chem. Neuropathol. 1993, 18:133-144.
104. Nagano-Saito A., Kato T., Arahata Y., Washimi Y., Nakamura A., Abe Y., Yamada T., Iwai K., Hatano K., Kawasumi Y., Kachi T., Dagher A., Ito K. Cognitive- and motor-related regions in Parkinson's disease: FDOPA and FDG PET studies. Neuroimage 2004, 22(2):553-561.
105. Nair V.D., Sealfon S.C. Agonist-specific transactivation of phosphoinositide 3-kinase signaling pathway mediated by the dopamine D2 receptor. J. Biol. Chem. 2003, 278:47053-47061.
106. Nichols D.E., Nichols C.D. Serotonin receptors. Chem. Rev. 2008, 108:1614-1641.
107. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog. Neurobiol. 2002, 67:53-83.
108. Nilsson A., Eriksson M., Muly E.C., Akesson E., Samuelsson E.B., Bogdanovic N., Benedikz E., Sundström E. Analysis of NR3A receptor subunits in human native NMDA receptors. Brain Res. 2007, 1186:102-112.
109. Oishi N., Hashikawa K., Yoshida H., Ishizu K., Ueda M., Kawashima H., Saji H., Fukuyama H. Quantification of nicotinic acetylcholine receptors in Parkinson's disease with (123)I-5IA SPECT. J. Neurol. Sci. 2007, 256:52-60.
110. Otani S., Auclair N., Desce J.M., Roisin M.P., Crepel F. Dopamine receptors and groups I and II mGluRs cooperate for long-term depression induction in rat prefrontal cortex through converging postsynaptic activation of MAP kinases. J. Neurosci. 1999, 19:9788-9802.
111. Panegyres P.K., Zafiris-Toufexis K., Kakulas B.A. The mRNA of the NR1 subtype of glutamate receptor in Alzheimer's disease. J. Neural Transm. 2002, 109:77-89.
112. Paoletti P., Neyton J. NMDA receptor subunits: function and pharmacology. Curr. Opin. Pharmacol. 2007, 7:39-47.
113. Pascual J., Grijalba B., Garcia-Sevilla J.A., Zarranz J.J., Pazos A. Loss of high-affinity alpha 2-adrenoceptors in Alzheimer's disease: an autoradiographic study in frontal cortex and hippocampus. Neurosci. Lett. 1992, 142:36-40.
114. Pascual M., Baliño P., Alfonso-Loeches S., Aragón C.M., Guerri C. Impact of TLR4 on behavioral and cognitive dysfunctions associated with alcohol-induced neuroinflammatory damage. Brain Behav. Immun. 2011, 25(Suppl. 1):S80-S91.
115. Paterson D., Nordberg A. Neuronal nicotinic receptors in the human brain. Prog. Neurobiol. 2000, 61(1):75-111.
116. Perez-García G., Meneses A. Oral administration of the 5-HT6 receptor antagonists SB-357134 and SB-399885 improves memory formation in an autoshaping learning task. Pharmacol. Biochem. Behav. 2005, 81(3):673-682.
117. Péron J., Vicente S., Leray E., Drapier S., Drapier D., Cohen R., Biseul I., Rouaud T., Le Jeune F., Sauleau P., Vérin M. Are dopaminergic pathways involved in theory of mind? A study in Parkinson's disease. Neuropsychologia 2009, 47(2):406-414.
118. Perry E.K., Perry R.H., Smith C.J., Purohit D., Bonham J., Dick D.J., Candy J.M., Edwardson J.A., Fairbairn A. Cholinergic receptors in cognitive disorders. Can. J. Neurol. Sci. 1986, 13:521-527.
119. Piccini P., Pavese N., Brooks D.J. Endogenous dopamine release after pharmacological challenges in Parkinson's disease. Ann. Neurol. 2003, 53(5):647-653.
120. Piggott M.A., Ballard C.G., Dickinson H.O., McKeith I.G., Perry R.H., Perry E.K. Thalamic D2 receptors in dementia with Lewy bodies. Parkinson's disease, and Parkinson's disease dementia. Int. J. Neuropsychopharmacol. 2007, 10:231-244.
121. Piggott M.A., Marshall E.F., Thomas N., Lloyd S., Court J.A., Jaros E., Burn D., Johnson M., Perry R.H., McKeith I.G., Ballard C., Perry E.K. Striatal dopaminergic markers in dementia with Lewy bodies. Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain 1999, 122(Pt 8):1449-1468.
122. Pizzolato G., Chierichetti F., Fabbri M., Cagnin A., Dam M., Ferlin G., Battistin L. Reduced striatal dopamine receptors in Alzheimer's disease: single photon emission tomography study with the D2 tracer [123I]-IBZM. Neurology 1996, 47:1065-1068.
123. Politis M., Piccini P., Pavese N., Koh S.B., Brooks D.J. Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride PET study. Exp. Neurol. 2008, 214:112-116.
124. Polter A.M., Li X. 5-HT1A receptor-regulated signal transduction pathways in brain. Cell. Signal. 2010, 22(10):1406-1412.
125. Poulin B., Butcher A., McWilliams P., Bourgognon J.M., Pawlak R., et al. The M3-muscarinic receptor regulates learning and memory in a receptor phosphorylation/arrestin-dependent manner. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(20):9440-9445.
126. Pralong E., Magistretti P., Stoop R. Cellular perspectives on the glutamate-monoamine interactions in limbic lobe structures and their relevance for some psychiatric disorders. Prog. Neurobiol. 2002, 67(3):173-202.
127. Proctor D.T., Coulson E.J., Dodd P.R. Post-synaptic scaffolding protein interactions with glutamate receptors in synaptic dysfunction and Alzheimer's disease. Prog. Neurobiol. 2011, 93(4):509-521.
128. Reeves S., Brown R., Howard R., Grasby P. Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer disease. Neurology 2009, 72:528-534.
129. Reeves S., Mehta M., Howard R., Grasby P., Brown R. The dopaminergic basis of cognitive and motor performance in Alzheimer's disease. Neurobiol. Dis. 2010, 37:477-482.
130. Reeves S.J., Grasby P.M., Howard R.J., Bantick R.A., Asselin M.C., Mehta M.A. A positron emission tomography (PET) investigation of the role of striatal dopamine (D2) receptor availability in spatial cognition. Neuroimage 2005, 28:216-226.
131. Rektorová I. Effects of dopamine agonists on neuropsychiatric symptoms of Parkinson's disease. Neurodegener. Dis. 2010, 7(1-3):206-209.
132. Rektorová I., Rektor I., Bares M., Dostál V., Ehler E., Fanfrdlová Z., Fiedler J., Klajblová H., Kulist'ák P., Ressner P., Svátová J., Urbánek K., Velísková J. Cognitive performance in people with Parkinson's disease and mild or moderate depression: effects of dopamine agonists in an add-on to L-DOPA therapy. Eur. J. Neurol. 2005, 12(1):9-15.
133. Rieckmann A., Karlsson S., Karlsson P., Brehmer Y., Fischer H., Farde L., Nyberg L., Bäckman L. Dopamine D1 receptor associations within and between dopaminergic pathways in younger and elderly adults: links to cognitive performance. Cereb. Cortex 2011, 21(9):2023-2032.
134. Rinne J.O., Myllykyla T., Lonnberg P., Marjamaki P. A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease. Brain Res. 1991, 547:167-170.
135. Roncarati R., Scali C., Comery T.A., Grauer S.M., Aschmi S., Bothmann H., Jow B., Kowal D., Gianfriddo M., Kelley C., Zanelli U., Ghiron C., Haydar S., Dunlop J., Terstappen G.C. Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders. J. Pharmacol. Exp. Ther. 2009, 329:459-468.
136. Rosse G., Schaffhauser H. 5-HT6 receptor antagonists as potential therapeutics for cognitive impairment. Curr. Top. Med. Chem. 2010, 10:207-221.
137. Ruat M., Traiffort E., Arrang J.M., Tardivel-Lacombe J., Diaz J., Leurs R., Schwartz J.C. A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation. Biochem. Biophys. Res. Commun. 1993, 193:268-276.
138. Russo-Neustadt A., Cotman C.W. Adrenergic receptors in Alzheimer's disease brain: selective increases in the cerebella of aggressive patients. J. Neurosci. 1997, 17:5573-5580.
139. Sabbagh M.N., Shah F., Reid R.T., Sue L., Connor D.J., Peterson L.K., Beach T.G. Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging. Arch. Neurol. 2006, 63:1771-1776.
140. Sabri O., Kendziorra K., Wolf H., Gertz H.J., Brust P. Acetylcholine receptors in dementia and mild cognitive impairment. Eur. J. Nucl. Med. Mol. Imaging 2008, 35(Suppl. 1):S30-S45.
141. Sawaguchi T. The role of D1-dopamine receptors in working memory-guided movements mediated by frontal cortical areas. Parkinsonism Relat. Disord. 2000, 7(1):9-19.
142. Sawamoto N., Piccini P., Hotton G., Pavese N., Thielemans K., Brooks D.J. Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. Brain 2008, 131:1294-1302.
143. Schechter L.E., Lin Q., Smith D.L., Zhang G., Shan Q., Platt B., Brandt M.R., Dawson L.A., Cole D., Bernotas R., Robichaud A., Rosenzweig-Lipson S., Beyer C.E. Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology 2008, 33:1323-1335.
144. Sharp S.I., Ballard C.G., Chen C.P., Francis P.T. Aggressive behavior and neuroleptic medication are associated with increased number of alpha1-adrenoceptors in patients with Alzheimer disease. Am. J. Geriatr. Psychiatr. 2007, 15:435-437.
145. Shen J.X., Yakel J.L. Nicotinic acetylcholine receptor-mediated calcium signaling in the nervous system. Acta Pharmacol. Sin. 2009, 30:673-680.
146. Shimohama S., Taniguchi T., Fujiwara M., Kameyama M. Biochemical characterization of alpha-adrenergic receptors in human brain and changes in Alzheimer-type dementia. J. Neurochem. 1986, 47:1295-1301.
147. Shimohama S., Taniguchi T., Fujiwara M., Kameyama M. Changes in beta-adrenergic receptor subtypes in Alzheimer-type dementia. J. Neurochem. 1987, 48:1215-1221.
148. Snyder E.M., Nong Y., Almeida C.G., Paul S., Moran T., Choi E.Y., Nairn A.C., Salter M.W., Lombroso P.J., Gouras G.K., Greengard P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat. Neurosci. 2005, 8:1051-1058.
149. Soliakov L., Wonnacott S. Involvement of protein kinase C in the presynaptic nicotinic modulation of [(3)H]-dopamine release from rat striatal synaptosomes. Br. J. Pharmacol. 2001, 132:785-791.
150. Stein J.L., Hua X., Morra J.H., Lee S., Hibar D.P., Ho A.J., Leow A.D., Toga A.W., Sul J.H., Kang H.M., Eskin E., Saykin A.J., Shen L., Foroud T., Pankratz N., Huentelman M.J., Craig D.W., Gerber J.D., Allen A.N., Corneveaux J.J., Stephan D.A., Webster J., DeChairo B.M., Potkin S.G., Jack C.R., Weiner M.W., Thompson P.M. Genome-wide analysis reveals novel genes influencing temporal lobe structure with relevance to neurodegeneration in Alzheimer's disease. Neuroimage 2010, 51:542-554.
151. Sumiyoshi T., Park S., Jayathilake K., Roy A., Ertugrul A., Meltzer H.Y. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr. Res. 2007, 95(1-3):158-168.
152. Sun H., Zhang J., Zhang L., Liu H., Zhu H., Yang Y. Environmental enrichment influences BDNF and NR1 levels in the hippocampus and restores cognitive impairment in chronic cerebral hypoperfused rats. Curr. Neurovasc. Res. 2010, 7:268-280.
153. Sun W., Sugiyama K., Fang X., Yamaguchi H., Akamine S., Magata Y., Namba H. Different striatal D2-like receptor function in an early stage after unilateral striatal lesion and medial forebrain bundle lesion in rats. Brain Res. 2010, 1317:227-235.
154. Sun W., Sugiyama K., Asakawa T., Yamaguchi H., Akamine S., Ouchi Y., Magata Y., Namba H. Dynamic changes of striatal dopamine D2 receptor binding at later stages after unilateral lesions of the medial forebrain bundle in Parkinsonian rat models. Neurosci. Lett. 2011, 496(3):157-162.
155. Szot P., White S.S., Greenup J.L., Leverenz J.B., Peskind E.R., Raskind M.A. Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies. J. Neurosci. 2006, 26:467-478.
156. Tanaka Y., Meguro K., Yamaguchi S., Ishii H., Watanuki S., Funaki Y., Yamaguchi K., Yamadori A., Iwata R., Itoh M. Decreased striatal D2 receptor density associated with severe behavioral abnormality in Alzheimer's disease. Ann. Nucl. Med. 2003, 17:567-573.
157. Truchot L., Costes N., Zimmer L., Laurent B., Le Bars D., Thomas-Anterion C., Mercier B., Hermier M., Vighetto A., Krolak-Salmon P. A distinct [18F]MPPF PET profile in amnestic mild cognitive impairment compared to mild Alzheimer's disease. Neuroimage 2008, 40:1251-1256.
158. Tsang S.W., Vinters H.V., Cummings J.L., Wong P.T., Chen C.P., Lai M.K. Alterations in NMDA receptor subunit densities and ligand binding to glycine recognition sites are associated with chronic anxiety in Alzheimer's disease. Neurobiol. Aging 2008, 29:1524-1532.
159. Tsang S.W., Lai M.K., Kirvell S., Francis P.T., Esiri M.M., Hope T., Chen C.P., Wong P.T. Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease. Neurobiol. Aging 2006, 27:1216-1223.
160. Turle-Lorenzo N., Maurin B., Puma C., Chezaubernard C., Morain P., Baunez C., Nieoullon A., Amalric M. The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease. J. Pharmacol. Exp. Ther. 2006, 319(2):914-923.
161. Turner T.J. Nicotine enhancement of dopamine release by a calcium-dependent increase in the size of the readily releasable pool of synaptic vesicles. J. Neurosci. 2004, 24(50):11328-11336.
162. Ulas J., Brunner L.C., Geddes J.W., Choe W., Cotman C.W. N-methyl-d-aspartate receptor complex in the hippocampus of elderly, normal individuals and those with Alzheimer's disease. Neuroscience 1992, 49:45-61.
163. Upton N., Chuang T.T., Hunter A.J., Virley D.J. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease. Neurotherapeutics 2008, 5:458-469.
164. Valjent E., Corvol J.C., Trzaskos J.M., Girault J.A., Herve D. Role of the ERK pathway in psychostimulant-induced locomotor sensitization. BMC Neurosci. 2006, 7:20.
165. Valjent E., Pascoli V., Svenningsson P., Paul S., Enslen H., Corvol J.C., Stipanovich A., Caboche J., Lombroso P.J., Nairn A.C., Greengard P., Herve D., Girault J.A. Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:491-496.
166. Verstappen C.C., Bloem B.R., Haaxma C.A., Oyen W.J., Horstink M.W. Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [123I]IBZM and [123I]FP-CIT SPECT study. Eur. J. Nucl. Med. Mol. Imaging 2007, 34:502-507.
167. Visanji N.P., Fox S.H., Johnston T.H., Millan M.J., Brotchie J.M. Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques. J. Pharmacol. Exp. Ther. 2009, 328(1):276-283.
168. Wang Q., Wang P.H., McLachlan C., Wong P.T. Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats. Brain Res. 2005, 1045:229-233.
169. Wang Q., Ting W.L., Yang H., Wong P.T. High doses of simvastatin upregulate dopamine D1 and D2 receptor expression in the rat prefrontal cortex: possible involvement of endothelial nitric oxide synthase. Br. J. Pharmacol. 2005, 144(7):933-939.
170. Wang Q., Zengin A., Ying W., Newell K.A., Wang P., Yeo W., Wong P.T., Yenari M.A., Huang X.F. Chronic treatment with simvastatin upregulates muscarinic M1/4 receptor binding in the rat brain. Neuroscience 2008, 154(3):1100-1106.
171. Wang Q., Zengin A., Deng C., Li Y., Newell K.A., Yang G.Y., Lu Y., Wilder-Smith E.P., Zhao H., Huang X.F. High dose of simvastatin induces hyperlocomotive and anxiolytic-like activities: the association with the up-regulation of NMDA receptor binding in the rat brain. Exp. Neurol. 2009, 216(1):132-138.
172. Ward R.J., Lallemand F., de Witte P., Dexter D.T. Neurochemical pathways involved in the protective effects of nicotine and ethanol in preventing the development of Parkinson's disease: potential targets for the development of new therapeutic agents. Prog. Neurobiol. 2008, 85(2):135-147.
173. West P.J., Marcy V.R., Marino M.J., Schaffhauser H. Activation of the 5-HT(6) receptor attenuates long-term potentiation and facilitates GABAergic neurotransmission in rat hippocampus. Neuroscience 2009, 164:692-701.
174. Wevers A., Schroder H. Nicotinic acetylcholine receptors in Alzheimer's disease. J. Alzheimers Dis. 1999, 1:207-219.
175. Wullner U., Testa C.M., Catania M.V., Young A.B., Penney J.B. Glutamate receptors in striatum and substantia nigra: effects of medial forebrain bundle lesions. Brain Res. 1994, 645:98-102.
176. Xiong H., McCabe L., Costello J., Anderson E., Weber G., Ikezu T. Activation of NR1a/NR2B receptors by soluble factors from APP-stimulated monocyte-derived macrophages: implications for the pathogenesis of Alzheimer's disease. Neurobiol. Aging 2004, 25:905-911.
177. Yan J., Xu Y., Zhu C., Zhang L., Wu A., Yang Y., Xiong Z., Deng C., Huang X.F., Yenari M.A., Yang Y.G., Ying W., Wang Q. Simvastatin prevents dopaminergic neurodegeneration in experimental Parkinsonian models: the association with anti-inflammatory responses. PLoS One 2011, 6(6):e20945.
178. Yasuno F., Suhara T., Nakayama T., Ichimiya T., Okubo Y., Takano A., Ando T., Inoue M., Maeda J., Suzuki K. Inhibitory effect of hippocampal 5-HT1A receptors on human explicit memory. Am. J. Psychiatr. 2003, 160:334-340.
179. Young J.W., Crawford N., Kelly J.S., Kerr L.E., Marston H.M., Spratt C., Finlayson K., Sharkey J. Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. Eur. Neuropsychopharmacol. 2007, 17:145-155.
180. Yu J.T., Tan L., Ou J.R., Zhu J.X., Liu K., Song J.H., Sun Y.P. Polymorphisms at the beta2-adrenergic receptor gene influence Alzheimer's disease susceptibility. Brain Res. 2008, 1210:216-222.
181. Yu S.P., Sensi S.L., Canzoniero L.M., Buisson A., Choi D.W. Membrane-delimited modulation of NMDA currents by metabotropic glutamate receptor subtypes 1/5 in cultured mouse cortical neurons. J. Physiol. 1997, 499(Pt 3):721-732.
182. Yu S.P., Yeh C., Strasser U., Tian M., Choi D.W. NMDA receptor-mediated K+ efflux and neuronal apoptosis. Science 1999, 284(5412):336-339.
183. Zhen X., Zhang J., Johnson G.P., Friedman E. D(4) dopamine receptor differentially regulates Akt/nuclear factor-kappa b and extracellular signal-regulated kinase pathways in D(4)MN9D cells. Mol. Pharmacol. 2001, 60(4):857-864.
184. Zhen X., Torres C., Cai G., Friedman E. Inhibition of protein tyrosine/mitogen-activated protein kinase phosphatase activity is associated with D2 dopamine receptor supersensitivity in a rat model of Parkinson's disease. Mol. Pharmacol. 2002, 62:1356-1363.